Actively Recruiting

Phase 2
Age: 40Years +
All Genders
NCT06967805

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Led by Mediar Therapeutics · Updated on 2026-05-06

164

Participants Needed

69

Research Sites

116 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

CONDITIONS

Official Title

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants with IPF of any gender aged 40 years or older at time of signing informed consent
  • Able to understand the study and provide signed, written informed consent
  • Able to read and understand the language of the informed consent and other trial materials
  • Meet 2019 ATS/ERS/JRS/ALAT criteria for IPF diagnosis; diagnosed within 7 years of screening
  • If on pirfenidone or nintedanib, dose must be stable for at least 90 days before screening and maintained during study; both agents cannot be used together
  • If discontinued pirfenidone or nintedanib, must have stopped at least 30 days before screening and no plans to restart during study
  • Forced vital capacity (FVC) of 45% predicted or higher at screening
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) of 25% predicted or higher at screening
  • Willing and able to complete all required study visits and procedures
  • Negative serum pregnancy test at screening for participants of childbearing potential
  • Agree to use medically approved contraception during the study if of reproductive potential
Not Eligible

You will not qualify if you...

  • Acute exacerbation of IPF within 6 months before or during screening
  • FEV1/FVC ratio less than 0.7 at screening
  • Need for continuous supplemental oxygen (intermittent use allowed)
  • Expected lung transplant during study period
  • Current active bacterial lung infection or recent antibiotic use within 30 days before screening
  • Planned surgery during study period
  • Clinically significant pulmonary hypertension
  • Use of immunosuppressive therapy (excluding corticosteroids) within required washout period
  • Use of systemic corticosteroids at 10 mg or higher daily within 30 days before screening
  • Current smoking or vaping
  • Current or recent (within 2 years) malignancy or lymphoproliferative disorder, except certain skin cancers
  • Current infection with hepatitis B, hepatitis C, or HIV
  • Pregnancy, breastfeeding, or planning conception during study
  • History of severe depression, psychosis, or suicidal thoughts within 2 years before screening
  • Any significant disease or lab abnormality interfering with study participation or safety
  • Elevated liver enzymes (AST or ALT more than twice the upper limit of normal) at screening
  • Known allergy to MTX-463 or its components
  • Prior use of MTX-463 or other WISP1-targeting therapies
  • Use of other investigational agents without appropriate washout before screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 69 locations

1

WISPer Site in Birmingham, AL

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

WISPer site in Phoenix, AZ

Phoenix, Arizona, United States, 85032

Actively Recruiting

3

WISPer Site in Los Angeles, CA

Los Angeles, California, United States, 90033

Actively Recruiting

4

WISPer site in Newport Beach, CA

Newport Beach, California, United States, 92663

Actively Recruiting

5

WISPer Site in Palm Springs, CA

Palm Springs, California, United States, 92203

Actively Recruiting

6

WISPer Site in Denver, CO

Denver, Colorado, United States, 80206

Actively Recruiting

7

WISPer site in Loxahatchee, FL

Loxahatchee Groves, Florida, United States, 33470

Actively Recruiting

8

WISPer Site in Atlanta, GA

Atlanta, Georgia, United States, 30322

Actively Recruiting

9

WISPer site in Champaign, IL

Champaign, Illinois, United States, 61822

Actively Recruiting

10

WISPer site in Kansas City, KS

Kansas City, Kansas, United States, 66160

Actively Recruiting

11

WISPer Site in Louisville, KY

Louisville, Kentucky, United States, 40202

Actively Recruiting

12

WISPer site in Shreveport, LA

Shreveport, Louisiana, United States, 71103

Actively Recruiting

13

WISPer Site in Baltimore, MD

Baltimore, Maryland, United States, 21224

Actively Recruiting

14

WISPer Site in Boston, MA

Boston, Massachusetts, United States, 02114

Actively Recruiting

15

WISPer Site in Ann Arbor, MI

Ann Arbor, Michigan, United States, 48209

Actively Recruiting

16

WISPer Site in Detroit, MI

Detroit, Michigan, United States, 48202

Actively Recruiting

17

WISPer site in New York, NY

New York, New York, United States, 10032

Actively Recruiting

18

WISPer Site in Durham, NC

Durham, North Carolina, United States, 27710

Actively Recruiting

19

WISPer site in Greensboro, NC

Greensboro, North Carolina, United States, 27403

Actively Recruiting

20

WISPer site in Oklahoma City, OK

Oklahoma City, Oklahoma, United States, 73104

Actively Recruiting

21

WISPer Site in Pittsburg, PA

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

22

WISPer Site in Charleston, SC

Charleston, South Carolina, United States, 29425

Actively Recruiting

23

WISPer Site in Nashville, TN

Nashville, Tennessee, United States, 37204

Actively Recruiting

24

WISPer site in Dallas, TX

Dallas, Texas, United States, 75204

Actively Recruiting

25

WISPer Site in Salt Lake City, UT

Salt Lake City, Utah, United States, 84103

Actively Recruiting

26

WISPer Site in Wilwaukee, WI

Milwaukee, Wisconsin, United States, 52226

Actively Recruiting

27

WISPer Site in Buenos Aires, Argentina

Buenos Aires, Argentina, B1602DQD

Actively Recruiting

28

WISPer Site in Cordoba, Argentina

Córdoba, Argentina, X5003DCE

Actively Recruiting

29

WISPer Site in Mendoza, Argentina

Mendoza, Argentina, M5500

Actively Recruiting

30

WISPer Site in Rosario, Argentina

Rosario, Argentina, S2000DBS

Actively Recruiting

31

WISPer Site in San Miguel De Tucumán, Argentina

San Miguel de Tucumán, Argentina, T4000IAI

Actively Recruiting

32

WISPer Site in Santa Fe, Argentina

Santa Fe, Argentina, S2000DBS

Actively Recruiting

33

WISPer Site in Santa Fe, Argentina

Santa Fe, Argentina, S3000ASF

Actively Recruiting

34

WISPer site in Greenslopes, Australia

Greenslopes, Australia, 4120

Actively Recruiting

35

WISPer site in Melbourne, Australia

Melbourne, Australia, 3004

Actively Recruiting

36

WISPer site in Midland, Australia

Midland, Australia, 6056

Actively Recruiting

37

WISPer site in Westmead, Australia

Westmead, Australia, 2145

Actively Recruiting

38

WISPer Site in Brussels, Belgium

Brussels, Belgium, 1200

Actively Recruiting

39

WISPer Site in Edegem, Belgium

Edegem, Belgium, 2650

Actively Recruiting

40

WISPer Site in Belo Horizonte, Brazil

Belo Horizonte, Brazil, 30110

Actively Recruiting

41

WISPer Site in Curitiba, Brazil

Curitiba, Brazil, 80060

Actively Recruiting

42

WISPer Site in Passo Fundo, Brazil

Passo Fundo, Brazil, 99010

Actively Recruiting

43

WISPer Site in Porto Alegre, Brazil

Porto Alegre, Brazil, 90035

Actively Recruiting

44

WISPer Site in Porto Alegre, Brazil

Porto Alegre, Brazil, 90410

Actively Recruiting

45

WISP Site in São Bernardo Do Campo, Brazil

São Bernardo do Campo, Brazil, 09715

Actively Recruiting

46

WISPer Site in Sao Paulo, Brazil

São Paulo, Brazil, 05403

Actively Recruiting

47

WISPer Site in Calgary, Alberta

Calgary, Alberta, Canada, T2N 4Z5

Actively Recruiting

48

WISPer site in Ajax, ON

Ajax, Ontario, Canada, L1S 2J5

Actively Recruiting

49

WISPer site in Trois-Rivières, Quebec

Trois-Rivières, Quebec, Canada, G8T 7A1

Actively Recruiting

50

WISPer Site in Split

Split, Croatia, 21000

Actively Recruiting

51

WISPer Site in Nantes, France

Nantes, France, 44800

Actively Recruiting

52

WISPer Site in Nice, France

Nice, France, 06001

Actively Recruiting

53

WISPer Site in Paris, France

Paris, France, 75015

Actively Recruiting

54

WISPer Site in Rennes, France

Rennes, France, 35033

Actively Recruiting

55

WISPer Site in Abbotstown, Ireland

Abbotstown, Ireland, D15 X40D

Actively Recruiting

56

WISPer Site in Drogheda, Ireland

Drogheda, Ireland, F92VW28

Actively Recruiting

57

WISPer Site in Dublin, Ireland

Dublin, Ireland, D24 NR0A

Actively Recruiting

58

WISPer Site in Letterkenny, Ireland

Letterkenny, Ireland, F92 AE81

Actively Recruiting

59

WISPer Site in Nieuwegein, Netherlands

Nieuwegein, Netherlands, 3435CM

Actively Recruiting

60

WISPer Site in Barcelona, Spain

Barcelona, Spain, 08017

Actively Recruiting

61

WISPer Site in Barcelona, Spain

Barcelona, Spain, 08036

Actively Recruiting

62

WISPer Site in Lugo, Spain

Lugo, Spain, 27003

Actively Recruiting

63

WISPer Site in Madrid, Spain 2

Madrid, Spain, 28050

Actively Recruiting

64

WISPer Site in Madrid, Spain

Madrid, Spain, 28223

Actively Recruiting

65

WISPer Site in Santander, Spain

Santander, Spain, 39008

Actively Recruiting

66

WISPer Site in Birmingham, UK

Birmingham, United Kingdom, B15 2GW

Actively Recruiting

67

WISPer Site in Cambridge, UK

Cambridge, United Kingdom, CB2 0BB

Actively Recruiting

68

WISPer Site in Edinburgh, UK

Edinburgh, United Kingdom, EH16 4SA

Actively Recruiting

69

WISPer Site in Oxford, UK

Oxford, United Kingdom, OX3 7LE

Actively Recruiting

Loading map...

Research Team

J

Jeffrey Bornstein, MD

CONTACT

K

Katherine Palu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | DecenTrialz